Insite Vision Inc Quick Ratio (INSV) starting from the second quarter 2015 to second quarter 2014, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Insite Vision Inc  (INSV)

Insite Vision Inc's Quick Ratio

INSV's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2015, Quick Ratio fell to 0.1 below Insite Vision Inc average.

Within Major Pharmaceutical Preparations industry 341 other companies have achieved higher Quick Ratio than Insite Vision Inc in second quarter 2015. While Quick Ratio total ranking has improved so far during the Q2 2015 to 4116, from total ranking in the first quarter 2015 at 4764.

Explain Quick Ratio?
How much Cash & cash equivalents INSV´s has?
What are INSV´s Current Liabilities?




INSV Quick Ratio (Jun 30 2015)
Q2
(Mar 31 2015)
Q1
(Dec 31 2014)
Q4
(Sep 30 2014)
Q3
(Jun 30 2014)
Q2
Y / Y Current Liabilities Change 237.74 % -79.27 % -78.35 % -28.19 % -57.8 %
Y / Y Cash & cash equivalent Change -29.09 % -80.38 % -79.93 % -97.11 % -83.06 %
Quick Ratio MRQ 0.1 0.1 0.16 0.06 0.48
INSV's Total Ranking # 4116 # 4764 # 4764 # 4382 # 4114
Seq. Current Liabilities Change 68.33 % -1.18 % 80.67 % 12.38 % -89.67 %
Seq. Cash & cash equivalent Change 67.14 % -36.59 % 401.82 % -86.67 % -53.76 %



Quick Ratio second quarter 2015 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 342
Healthcare Sector # 685
Overall Market # 4116


Quick Ratio Statistics
High Average Low
16.04 2.26 0.06
(Dec 31 2010)   (Sep 30 2014)




Financial Statements
Insite Vision Inc's Current Liabilities $ 17 Millions Visit INSV's Balance sheet
Insite Vision Inc's Cash & cash equivalent $ 2 Millions Visit INSV's Balance sheet
Source of INSV's Sales Visit INSV's Sales by Geography


Cumulative Insite Vision Inc's Quick Ratio

INSV's Quick Ratio for the trailling 12 Months

INSV Quick Ratio

(Jun 30 2015)
12 Months
(Mar 31 2015)
12 Months
(Dec 31 2014)
12 Months
(Sep 30 2014)
12 Months
(Jun 30 2014)
12 Months
Y / Y Current Liabilities TTM Growth -60.51 % -73.2 % -14.8 % 104.17 % 85.68 %
Y / Y Cash & cash equivalent TTM Growth -82.58 % -86.1 % -74.68 % -58.8 % -33.92 %
Quick Ratio TTM 0.11 0.17 0.14 0.15 0.25
Total Ranking TTM # 4190 # 2941 # 2944 # 3925 # 3720
Seq. Current Liabilities TTM Growth 38.59 % -55.46 % -34.69 % -2.04 % -5.96 %
Seq. Cash & cash equivalent TTM Growth -13.06 % -43.85 % -40.19 % -40.34 % -30.62 %


On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2015 to $17.43 millions, cumulative Quick Ratio decreased to 0.11 below the Insite Vision Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 246 other companies have achieved higher Quick Ratio than Insite Vision Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2015 from 2941 to 4190.

Explain Quick Ratio?
How much Cash & cash equivalents INSV´s has?
What are INSV´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 247
Healthcare Sector # 560
Within the Market # 4190


trailing twelve months Quick Ratio Statistics
High Average Low
0.74 0.3 0.11
(Sep 30 2013)   (Jun 30 2015)




Companies with similar Quick Ratio in the quarter ending Jun 30 2015, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2015 MRQ Cash & cash equivalentJun 30 2015 MRQ Current Liabilities
Intellipharmaceutics International Inc   0.27 $ 0.761  Millions$ 2.791  Millions
Ainos Inc   0.27 $ 0.100  Millions$ 0.371  Millions
Igc Pharma Inc   0.25 $ 0.660  Millions$ 2.594  Millions
Lifecore Biomedical Inc   0.25 $ 14.127  Millions$ 56.159  Millions
Phibro Animal Health Corporation  0.24 $ 29.216  Millions$ 119.411  Millions
Bausch Health Companies Inc   0.22 $ 958.000  Millions$ 4,291.000  Millions
American Bio Medica Corporation  0.20 $ 0.433  Millions$ 2.163  Millions
Theriva Biologics inc   0.19 $ 4.757  Millions$ 25.498  Millions
Northwest Biotherapeutics Inc  0.17 $ 20.223  Millions$ 116.546  Millions
Allergan plc  0.16 $ 1,551.500  Millions$ 9,571.400  Millions
Cytodyn inc   0.16 $ 1.050  Millions$ 6.651  Millions
Cardax Inc   0.15 $ 0.673  Millions$ 4.602  Millions
Vaccinogen Inc  0.14 $ 0.965  Millions$ 7.133  Millions
Wellness Center Usa Inc  0.13 $ 0.128  Millions$ 0.959  Millions
Teva Pharmaceutical Industries Limited  0.13 $ 1,068.000  Millions$ 8,019.000  Millions
Nanomix Corp  0.12 $ 0.208  Millions$ 1.720  Millions
Mylan N v   0.11 $ 587.000  Millions$ 5,369.400  Millions
Cnbx Pharmaceuticals Inc   0.11 $ 0.022  Millions$ 0.203  Millions
Xenetic Biosciences Inc   0.11 $ 0.367  Millions$ 3.469  Millions
Insite Vision Inc  0.10 $ 1.755  Millions$ 17.431  Millions
International Stem Cell Corporation  0.10 $ 0.554  Millions$ 5.830  Millions
Generex Biotechnology Corp  0.09 $ 0.750  Millions$ 8.019  Millions
Imagenetix Inc  0.09 $ 0.092  Millions$ 0.996  Millions
Bioadaptives Inc   0.09 $ 0.012  Millions$ 0.133  Millions
Sunwin Stevia International Inc.  0.09 $ 0.522  Millions$ 6.001  Millions
Musclepharm Corporation  0.08 $ 4.170  Millions$ 54.243  Millions
Nascent Biotech Inc   0.07 $ 0.107  Millions$ 1.539  Millions
Abvc Biopharma Inc   0.06 $ 0.002  Millions$ 0.037  Millions
Whitehawk Therapeutics Inc   0.06 $ 0.010  Millions$ 0.178  Millions
Novaccess Global Inc  0.05 $ 0.033  Millions$ 0.645  Millions

Date modified: 2026-08-29T17:23:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.